Evoke Pharma Secures Two New Patents For GIMOTI Nasal Spray, Expanding IP Portfolio December 03, 2024 — 10:24 am EST Written by RTTNews.com for RTTNews -> ...

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036.

About Gimoti™ (metoclopramide) nasal spray GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information ...

About Gimoti™ (metoclopramide) nasal spray GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information ...

Evoke Pharma announced a patent allowance for GIMOTI® nasal spray, enhancing its protection for treating diabetic gastroparesis. Quiver AI Summary Evoke Pharma, Inc. announced that it has ...

Evoke Pharma Inc (NASDAQ:EVOK) saw its stock soar 50% after the specialty pharma company received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering ...

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Patients treated with Gimoti® (metoclopramide) nasal spray showed statistically significant fewer emergency department visits, inpatient hospitalizations, and physician office visits than ...